Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The clinical implications of being able to accurately detect tumor-derived DNA in the circulation, termed circulating tumor DNA (ctDNA), could be enormous. Already, a plethora of clinical applications is under validation that include detection of minimal residual disease and predicting recurrence, monitoring response and resistance to treatment, identifying targets for therapies, and early detection. ctDNA is only a fraction of the total cell-free DNA (cfDNA) which confounds its detection and sometimes conceals its properties. To use ctDNA as a cancer biomarker with confidence, we need to understand its nature. Its characteristics, including size, half-life, and amount, are critical for the development of tests for its detection and discrimination from the rest of the cfDNA. Technological advances have enabled the detection and quantification of individual fragments of cfDNA, which is pivotal for clinical applications. Understanding the causes, the source of and the mechanisms of release of ctDNA are important for the interpretation of test results. Despite the many advances in understanding the nature and biology of ctDNA, we do not yet have a clear appreciation of the processes that govern its presence and levels in the circulation. ctDNA is not detectable in the blood of every cancer patient, and there is not a directly proportional relationship to tumor type, size, or stage. It is not clear if the lack of correlation with these specific clinical parameters is strictly due to technical or biological challenges. Better understanding of the pathophysiology of ctDNA is therefore important for the improvement of clinical applications and interpretation of their results.

Original languageEnglish (US)
Title of host publicationRecent Results in Cancer Research
PublisherSpringer New York LLC
Pages163-180
Number of pages18
DOIs
StatePublished - Jan 1 2020

Publication series

NameRecent Results in Cancer Research
Volume215
ISSN (Print)0080-0015
ISSN (Electronic)2197-6767

Fingerprint

DNA
Neoplasms
Residual Neoplasm
Tumor Biomarkers
Half-Life
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Papadopoulos, N. (2020). Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. In Recent Results in Cancer Research (pp. 163-180). (Recent Results in Cancer Research; Vol. 215). Springer New York LLC. https://doi.org/10.1007/978-3-030-26439-0_9

Pathophysiology of ctDNA Release into the Circulation and Its Characteristics : What Is Important for Clinical Applications. / Papadopoulos, Nickolas.

Recent Results in Cancer Research. Springer New York LLC, 2020. p. 163-180 (Recent Results in Cancer Research; Vol. 215).

Research output: Chapter in Book/Report/Conference proceedingChapter

Papadopoulos, N 2020, Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. in Recent Results in Cancer Research. Recent Results in Cancer Research, vol. 215, Springer New York LLC, pp. 163-180. https://doi.org/10.1007/978-3-030-26439-0_9
Papadopoulos N. Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. In Recent Results in Cancer Research. Springer New York LLC. 2020. p. 163-180. (Recent Results in Cancer Research). https://doi.org/10.1007/978-3-030-26439-0_9
Papadopoulos, Nickolas. / Pathophysiology of ctDNA Release into the Circulation and Its Characteristics : What Is Important for Clinical Applications. Recent Results in Cancer Research. Springer New York LLC, 2020. pp. 163-180 (Recent Results in Cancer Research).
@inbook{e5fb932543854eb2913b10d5f23647bc,
title = "Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications",
abstract = "The clinical implications of being able to accurately detect tumor-derived DNA in the circulation, termed circulating tumor DNA (ctDNA), could be enormous. Already, a plethora of clinical applications is under validation that include detection of minimal residual disease and predicting recurrence, monitoring response and resistance to treatment, identifying targets for therapies, and early detection. ctDNA is only a fraction of the total cell-free DNA (cfDNA) which confounds its detection and sometimes conceals its properties. To use ctDNA as a cancer biomarker with confidence, we need to understand its nature. Its characteristics, including size, half-life, and amount, are critical for the development of tests for its detection and discrimination from the rest of the cfDNA. Technological advances have enabled the detection and quantification of individual fragments of cfDNA, which is pivotal for clinical applications. Understanding the causes, the source of and the mechanisms of release of ctDNA are important for the interpretation of test results. Despite the many advances in understanding the nature and biology of ctDNA, we do not yet have a clear appreciation of the processes that govern its presence and levels in the circulation. ctDNA is not detectable in the blood of every cancer patient, and there is not a directly proportional relationship to tumor type, size, or stage. It is not clear if the lack of correlation with these specific clinical parameters is strictly due to technical or biological challenges. Better understanding of the pathophysiology of ctDNA is therefore important for the improvement of clinical applications and interpretation of their results.",
author = "Nickolas Papadopoulos",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/978-3-030-26439-0_9",
language = "English (US)",
series = "Recent Results in Cancer Research",
publisher = "Springer New York LLC",
pages = "163--180",
booktitle = "Recent Results in Cancer Research",

}

TY - CHAP

T1 - Pathophysiology of ctDNA Release into the Circulation and Its Characteristics

T2 - What Is Important for Clinical Applications

AU - Papadopoulos, Nickolas

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The clinical implications of being able to accurately detect tumor-derived DNA in the circulation, termed circulating tumor DNA (ctDNA), could be enormous. Already, a plethora of clinical applications is under validation that include detection of minimal residual disease and predicting recurrence, monitoring response and resistance to treatment, identifying targets for therapies, and early detection. ctDNA is only a fraction of the total cell-free DNA (cfDNA) which confounds its detection and sometimes conceals its properties. To use ctDNA as a cancer biomarker with confidence, we need to understand its nature. Its characteristics, including size, half-life, and amount, are critical for the development of tests for its detection and discrimination from the rest of the cfDNA. Technological advances have enabled the detection and quantification of individual fragments of cfDNA, which is pivotal for clinical applications. Understanding the causes, the source of and the mechanisms of release of ctDNA are important for the interpretation of test results. Despite the many advances in understanding the nature and biology of ctDNA, we do not yet have a clear appreciation of the processes that govern its presence and levels in the circulation. ctDNA is not detectable in the blood of every cancer patient, and there is not a directly proportional relationship to tumor type, size, or stage. It is not clear if the lack of correlation with these specific clinical parameters is strictly due to technical or biological challenges. Better understanding of the pathophysiology of ctDNA is therefore important for the improvement of clinical applications and interpretation of their results.

AB - The clinical implications of being able to accurately detect tumor-derived DNA in the circulation, termed circulating tumor DNA (ctDNA), could be enormous. Already, a plethora of clinical applications is under validation that include detection of minimal residual disease and predicting recurrence, monitoring response and resistance to treatment, identifying targets for therapies, and early detection. ctDNA is only a fraction of the total cell-free DNA (cfDNA) which confounds its detection and sometimes conceals its properties. To use ctDNA as a cancer biomarker with confidence, we need to understand its nature. Its characteristics, including size, half-life, and amount, are critical for the development of tests for its detection and discrimination from the rest of the cfDNA. Technological advances have enabled the detection and quantification of individual fragments of cfDNA, which is pivotal for clinical applications. Understanding the causes, the source of and the mechanisms of release of ctDNA are important for the interpretation of test results. Despite the many advances in understanding the nature and biology of ctDNA, we do not yet have a clear appreciation of the processes that govern its presence and levels in the circulation. ctDNA is not detectable in the blood of every cancer patient, and there is not a directly proportional relationship to tumor type, size, or stage. It is not clear if the lack of correlation with these specific clinical parameters is strictly due to technical or biological challenges. Better understanding of the pathophysiology of ctDNA is therefore important for the improvement of clinical applications and interpretation of their results.

UR - http://www.scopus.com/inward/record.url?scp=85073166947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073166947&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-26439-0_9

DO - 10.1007/978-3-030-26439-0_9

M3 - Chapter

C2 - 31605229

AN - SCOPUS:85073166947

T3 - Recent Results in Cancer Research

SP - 163

EP - 180

BT - Recent Results in Cancer Research

PB - Springer New York LLC

ER -